Results 51 to 60 of about 202,276 (321)

Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile [PDF]

open access: yes, 2009
The human REL proto-oncogene encodes a transcription factor in the nuclear factor (NF)-kappaB family. Overexpression of REL is acutely transforming in chicken lymphoid cells, but has not been shown to transform any mammalian lymphoid cell type.
Chin, M.   +4 more
core   +2 more sources

Burkitt lymphoma versus diffuse large B-cell lymphoma

open access: yesAnnals of Oncology, 2008
Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) represent distinct entities among aggressive B-cell non-Hodgkin lymphomas (B-NHLs) in the WHO classification [1]. According to the clinical setting of the occurrence, endemic, sporadic and immunodeficiency-associated BL can be distinguished as clinical variants.
A, Rosenwald, G, Ott
openaire   +2 more sources

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

open access: yesMolecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian   +10 more
wiley   +1 more source

Retrospective Analysis of Pemetrexed-based Chemotherapy Regimens on Mid-elderly Non-Hodgkin's Lymphoma

open access: yesZhongliu Fangzhi Yanjiu, 2020
Objective To analyze the safety and efficacy of pemetrexed-based chemotherapy on patients with mid-elderly non-Hodgkin's lymphoma. Methods We retrospectively reviewed the clinical data of patients with non-Hodgkin's lymphoma treated with pemetrexed-based
WEN Tingyu   +6 more
doaj   +1 more source

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

open access: yesMolecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert   +13 more
wiley   +1 more source

Primary thyroid lymphoma: A rare disease

open access: yesJournal of Cytology, 2014
Primary thyroid lymphomas are rare neoplasms comprising of 1-5% of thyroid malignancies. These are predominantly B-cell in origin. Here, we report a case of 60 years lady, a known case of lymphocytic thyroiditis, diagnosed as thyroid lymphoma (diffuse ...
Deepti Verma   +3 more
doaj   +1 more source

Diffuse large B-cell lymphoma, not otherwise specified of the palate: a case report [PDF]

open access: yes, 2013
Diffuse large B-cell lymphoma (DLBCL) is the most frequent type of non-Hodgkin´s lymphoma found in oral and maxillofacial regions. A large number of cases may be biologically heterogeneous, which are commonly defined as DLBCL, not otherwise specified ...
Castro, Alexandre Fonseca de   +3 more
core   +1 more source

Correlation of the differential expression of PIK3R1 and its spliced variant, p55α, in pan‐cancer

open access: yesMolecular Oncology, EarlyView.
PIK3R1 undergoes alternative splicing to generate the isoforms, p85α and p55α. By combining large patient datasets with laboratory experiments, we show that PIK3R1 spliced variants shape cancer behavior. While tumors lose the protective p85α isoform, p55α is overexpressed, changes linked to poorer survival and more pronounced in African American ...
Ishita Gupta   +10 more
wiley   +1 more source

T-cell/histiocyte-rich large B-cell lymphoma presenting as a primary central nervous system lymphoma

open access: yesRare Tumors, 2015
Primary central nervous system (PCNSL) lymphoma is an aggressive extranodal non-Hodgkin lymphoma, and most cases are classified as diffuse large B-cell lymphoma (DLBCL) by histology.
Pooja Advani   +6 more
doaj   +1 more source

Is now the time for molecular driven therapy for diffuse large B-cell lymphoma? [PDF]

open access: yes, 2017
INTRODUCTION: Recent genetic and molecular discoveries regarding alterations in diffuse large B-cell lymphoma (DLBCL) deeply changed the approach to this lymphoproliferative disorder.
Ansuinelli, Michela   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy